The Latest in Triple Negative Breast Cancer [Webchat]

0

Triple-negative breast cancer (TNBC), which makes up about 10 to 15 percent of all breast cancers, describes breast cancer cells that do not have estrogen, progesterone, or HER2 receptors.

In a recent Facebook Live webchat, Ann Partridge, MD, MPH, Director of the Program for Young Women with Breast Cancer in the Susan F. Smith Center for Women’s Cancers at Dana-Farber, discussed treatment for this disease, as well as promising new advancements in areas such as immunotherapy.

Ann Partridge, MD, MPH.

“The good news is that we are making headway — there are a lot of newer therapies that seem to be showing great promise,” Partridge said. “So I’m very optimistic.”

Immunotherapy is not yet available as a standard treatment for patients with breast cancer. However, some clinical trials have shown that some pre-operative breast cancer patients, especially those with TNBC, responded well to a combination of immunotherapy and chemotherapy, according to Partridge.

During the chat, Partridge also discussed why TNBC in often found in younger women and in women of African American or Hispanic background; what particular challenges face young women with breast cancer; and who is at risk for this kind of breast cancer, including women with the BRCA-1 mutation.

View a video of the August 1 webchat below.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
What is the Relationship Between Tea and #Cancer Prevention? https://t.co/mnYP2qfjtW https://t.co/N5LVaBSRZ2
Dana-Farber @danafarber
Missed Dana-Farber at #ASH17? Subscribe to our bi-annual e-newsletter, Advances in Hematologic Malignancies, to lea… https://t.co/kknkzq1qmL
Dana-Farber @danafarber
Congratulations to Dr. Edward Benz, president and chief executive officer emeritus of Dana-Farber Cancer Institute,… https://t.co/YH71ia6nn2

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.